Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Jacobson Invests $15 Million in Shanghai Henlius; Obtains Hong Kong Rights to Biosimilar

publication date: Dec 20, 2017

Jacobson Pharma in-licensed Hong Kong rights to a Herceptin biosimilar being developed by Shanghai Henlius Biotech. To obtain the rights, Jacobson will make a $15 million investment in Henlius, a biotech JV started in 2009 by Fosun Pharma and Henlius Biotech. Jacobson will own the Hong Kong and Macau rights to the candidate for ten years and have first refusal rights in other ASEAN countries. The $15 million investment constitutes 8% of the $190 million Henlius is seeking in its current fundraising, according to the official press release. More details....

Stock Symbols: (HK: 2633) (SHA: 600196; HK: 2196)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.